{"brief_title": "Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease", "brief_summary": "OBJECTIVES: I. Evaluate the effects of androgen suppression with leuprolide and androgen replacement with testosterone enanthate on muscle strength in men with Kennedy's disease or other motor neuron disease.", "detailed_description": "PROTOCOL OUTLINE: All patients receive androgen suppression with leuprolide acetate injections every 4 weeks for 6 months, plus hormone replacement therapy with testosterone enanthate injections every week for 24 weeks.", "condition": ["Spinal Muscular Atrophy", "Amyotrophic Lateral Sclerosis", "Spinobulbar Muscular Atrophy"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["leuprolide", "testosterone"], "criteria": "PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Men aged 18 and over with motor neuron disease, i.e.: - X-linked spinal and bulbar muscular atrophy (Kennedy's disease) - Confirmed by androgen receptor, exon-1 mutation genotype - Amyotrophic lateral sclerosis - Spinal muscular atrophy Significant muscle weakness on manual muscle testing No prisoners No mental disability", "gender": "Male", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Kennedy's Syndrome", "mesh_term": ["Sclerosis", "Atrophy", "Motor Neuron Disease", "Amyotrophic Lateral Sclerosis", "Muscular Atrophy, Spinal", "Muscular Atrophy", "Muscular Disorders, Atrophic", "Leuprolide", "Methyltestosterone", "Testosterone", "Testosterone enanthate", "Testosterone undecanoate", "Testosterone 17 beta-cypionate"], "id": "NCT00004771"}